STADA

Company History

Company History

2014

  • STADA exceeds two-billion-euro mark in sales
  • Purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat

 

2013

  • Optimization of German sales
  • Establishment of an IT shared service center for the group in Serbia
  • Acquisition of the British OTC provider Thornton & Ross
  • Introduction of a 2D barcode as the first pharmaceutical company in Germany
  • Introduction of the personalized drug therapy business with "STADA diagnostics"
  • Establishment of a logistics and distribution center in Dubai

 

2012

  • Sale of two of the four Russian production facilities in Moscow and Ryazanskaya
  • Foundation of a subsidiary in Australia
  • Sale of the Irish production facility STADA Production Ireland Limited
  • Purchase of a branded product portfolio for EU markets in Central Europe
  • Purchase of a generics business in Switzerland

 

2011

  • Purchase of a branded product portfolio for Eastern Europe and the Middle East
  • Cooperation for the development of two biosimilar products
  • Acquisition of the British branded product Cetraben®

 

2007

  • Acquisition of the British Forum Bioscience group
  • Acquisition of the Russian MAKIZ group

 

2006

  • Acquisition of the Serbian Hemofarm Group
  • Sale of US subsidiary

 

2005

  • Acquisition of a package of eleven European branded products (amongst others Mobilat®)
  • STADA acquired a 58% stake in the Chinese pharmaceuticals manufacturing company BCP
  • Acquisition of the Portuguese generics supplier Ciclum Farma
  • Acquisition of approx. 97.5% of the shares in the Russian pharmaceuticals company, Nizhpharm

 

2004

  • Acquisition of a portfolio of Branded Products in Italy
  • De facto 1:1 stock split
  • Early Entry Mirtazapine

 

2003

  • Capital measures raised total net funds of EUR 256.4 million
  • Acquisition of a package of branded products from redinomedica, for the German OTC market
  • Acquisition of UK generics supplier Schein Pharmaceuticals with generics sales line Genus
  • Acquisition of 60% stake in Italy's NPA, a sales specialist in the pharmacy sector
  • For the first time: Market capitalization > EUR 1 billion

 

2002

  • Start of operations in the USA with the sales company STADA Pharmaceuticals Inc. after acquiring the business of the US generics supplier MOVA Laboratories
  • Acquisition of marketing and sales activities of Italian pharmaceutical company Crinos
  • Acquisition of Spanish generics supplier Bayvit S.A.
  • STADA increases stake in Spanish brand supplier Ciclum Farma to 100%
  • Acquisition of numerous local branded products
  • Conversion from German accounting standards (HGB) to IAS
  • Inclusion in EuroSTOXX 600 stock index

 

2001

  • Sales exceed the EUR 500 million threshold
  • Conversion of preferred shares into registered common shares
  • STADA common stock is included in the German mid-cap index, MDAX
  • Majority investments in the Philippines (Croma Medic Ltd.)
  • Start-up of biogenerics cooperation with DSM, utilizing private venture capital

 

2000

  • Stock split 1:10 for common and preferred stock
  • Acquisition of Clonmel Healthcare Ltd., the leader in the Irish generics market

 

1999

  • Start-up of STADA Asiatic Co. Ltd., Bangkok
  • Investment in Spain in Ciclum Farma, Madrid
  • Start-up in Italy with EG S.p.A., Milan

 

1998

  • Conclusion of the process of going public with registered common stock
  • Acquisition in Denmark (PharmaCoDane Aps)
  • Positioning as comprehensive supplier in the health care market with the acquisition of oncologics (cell pharm) and a package of discretionary prescription brands from Fresenius

 

1997

  • Beginning of process of going public with non-voting preferred stock

 

1996

  • Purchase of ALIUD PHARMA as second generics line in Germany
  • Expansion into France (EG Laboratoires EuroGenerics S.A.) and the Czech Republic (ALIUD PHARMA CZ s.r.o.)

 

1995

  • Expansion of the STADA Group structure with market-oriented sales companies

 

1992

  • Start-up in Asia with STADA Pharmaceuticals (Asia) Ltd. in Hong Kong

 

1991

  • Acquisitions in the Netherlands (Centrafarm B.V.) and in Belgium (N.V. Eurogenerics S.A.)

 

1986

  • Beginning of internationalization (Helvepharm AG/Switzerland, STADA Arzneimittel/Austria)

 

1975

  • Entry into the emerging generics market

 

1970

  • STADA becomes a stock corporation with registered shares exclusively for pharmacists

 

1956

  • Move to the present location in Bad Vilbel

 

1948

  • New beginning at the locations in Essen and Tübingen with products for self-medication

 

1895

  • Founded in Dresden as a pharmacists' cooperative
Company Profile

Company Profile

As one of the world's leading generic manufacturer, we offer affordable and high-quality medicines and healthcare products for more than 100 years.

To Company Profile

Career

Career

Build your career with us. Learn all about the training opportunities at STADA.

Learn more

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

entdecken